These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 11137565)
1. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells. Lopes EC; Scolnik M; Alvarez E; Hajos SE Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565 [TBL] [Abstract][Full Text] [Related]
2. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines. van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167 [TBL] [Abstract][Full Text] [Related]
3. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. Jiang XR; Kelsey SM; Wu YL; Newland AC Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760 [TBL] [Abstract][Full Text] [Related]
5. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Watanabe T; Tsuge H; Oh-Hara T; Naito M; Tsuruo T Acta Oncol; 1995; 34(2):235-41. PubMed ID: 7718262 [TBL] [Abstract][Full Text] [Related]
6. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Friche E; Jensen PB; Nissen NI Cancer Chemother Pharmacol; 1992; 30(3):235-7. PubMed ID: 1628375 [TBL] [Abstract][Full Text] [Related]
7. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771 [TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Naito M; Oh-hara T; Yamazaki A; Danki T; Tsuruo T Cancer Chemother Pharmacol; 1992; 29(3):195-200. PubMed ID: 1370765 [TBL] [Abstract][Full Text] [Related]
9. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202 [TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. Fridborg H; Larsson R; Juhlin C; Rastad J; Akerström G; Backlin K; Nygren P Anticancer Res; 1994; 14(3A):1009-16. PubMed ID: 7915506 [TBL] [Abstract][Full Text] [Related]
11. The efflux of anthracyclines in multidrug-resistant cell lines. Coley HM; Twentyman PR; Workman P Biochem Pharmacol; 1993 Oct; 46(8):1317-26. PubMed ID: 7902089 [TBL] [Abstract][Full Text] [Related]
12. Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. Nygren P; Larsson R Int J Cancer; 1991 Jun; 48(4):598-604. PubMed ID: 2045203 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339 [TBL] [Abstract][Full Text] [Related]
15. Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression. Chao CC FEBS Lett; 1995 Oct; 373(3):285-90. PubMed ID: 7589484 [TBL] [Abstract][Full Text] [Related]
16. Correlation between functional and molecular analysis of mdr1 P-glycoprotein in human solid-tumor xenografts. Broxterman HJ; Feller N; Kuiper CM; Boven E; Versantvoort CH; Teerlink T; Pinedo HM; Lankelma J Int J Cancer; 1995 Jun; 61(6):880-6. PubMed ID: 7790125 [TBL] [Abstract][Full Text] [Related]
17. Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents. Quesada AR; Barbacid MM; Mira E; Aracil M; Márquez G Cancer Lett; 1996 Jan; 99(1):109-14. PubMed ID: 8564921 [TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of cyclosporin A and verapamil in overcoming vincristine resistance of multidrug-resistant cultured human leukemia cells. Ishida Y; Shimada Y; Shimoyama M Jpn J Cancer Res; 1990 Aug; 81(8):834-41. PubMed ID: 2118896 [TBL] [Abstract][Full Text] [Related]
19. Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA. Dietel M; Herzig I; Reymann A; Brandt I; Schaefer B; Bunge A; Heidebrecht HJ; Seidel A J Cancer Res Clin Oncol; 1994; 120(5):263-71. PubMed ID: 7907333 [TBL] [Abstract][Full Text] [Related]
20. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Ganapathi R; Kuo T; Teeter L; Grabowski D; Ford J Mol Pharmacol; 1991 Jan; 39(1):1-8. PubMed ID: 1670962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]